James Carroll

James Carroll is President and CEO of RNA NanoBiotics, Inc., a biotechnology company pioneering targeted RNA architectures for oncology drug delivery. He brings more than 25 years of leadership experience across the life sciences sector, including senior roles at Waters Corporation, Bio-Rad, and as Chief Business Officer at Remedium Bio, a gene-therapy company developing engineered delivery systems for durable, tissue-targeted gene expression.

At RNA NanoBiotics, Mr. Carroll leads the company’s platform strategy and clinical translation efforts, overseeing the integration of RNA structural engineering, translational oncology, and regulatory pathway planning to advance targeted therapeutics toward the clinic. The company’s approach emphasizes structure-encoded targeting, modular payload design, and favorable biodistribution, including minimal nonspecific uptake, rapid renal clearance of unbound material, and limited liver accumulation.
In addition, Mr. Carroll serves as President of Wharton Alumni Angels, leading a global network of over 400 investors focused on innovation and entrepreneurship. His expertise spans company building, strategic commercialization, and capital formation for early-stage biotechnology ventures, with a strong emphasis on translating differentiated delivery platforms into clinically and commercially viable medicines.